Interim report for first quarter 2022
A broader and stronger licensing business strengthens our position in infection preventionFirst quarter (January-March 2022) · Revenues amounted to SEK 55.2 (41.8) million, an increase of 32%, mainly through higher licensing revenues. Adjusted for currency the increase was 23%. · EBITDA amounted to SEK -4.0 (1.9) million with an EBITDA-margin of -7% (5%), a result of initiated investments in accordance with the focused growth strategy. · Operating profit amounted to SEK -16.6 (-9.7) million. · Net loss for the period amounted to SEK -16.5 (-10.5) million. Earnings per share